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Purpose/Objective: Stereotactic body radiation therapy (SBRT) has 
emerged as an effective treatment option for hepatic metastases. We 
evaluated the intrafractional movement of liver metastases during 
SBRT using helical Tomotherapy. 
Materials and Methods: From april 2011 onwards we treated twelve 
patients with hepatic metastases with SBRT. A dose of 60 Gy in 3-6 
fractions was administered. Before the start of RT, we implanted 
three gold markers around the metastasis for setup and for movement 
visualization due to respiration. We used the Body Pro-Loktm System 
with an abdominal compression plate combined with a vacuum 
cushion for immobilization. The compression plate was placed right 
under the xyphoid to reduce liver movement. A respiratory-correlated 
4DCT was made to determine the maximum extreme positions of the 
markers during respiration. In general a radial margin of 6 mm and a 
cranial-caudal (CC) margin of 10 mm from GTV to PTV was used. The 
difference between end-inhalation (EI) and end-exhalation (EE) was 
used to adapt these margins. The tumor was delineated on a average 
CT registered with a contrast CT and a MRI. Before the delivery of 
each fraction, a pre-treatment MVCT was performed and matched 
with the planning CT. Since this MVCT is a slow scan, respiratory 
movements result in a blurred representation of the markers. We 
verified that the center of this blurred signal corresponds with the 
center of mass of the marker. After each treatment, all patients 
underwent a post-treatment MVCT. The gold markers shifts between 
the pre- and post-treatment MVCT were determined to quantify the 
intrafractional movements. 
Results: We evaluated 42 MVCT’s from twelve patients. The median 
intrafractional marker movement for all patients was 0.6 mm (range, 
0 - 2.9 mm), 1.3 mm (range, 0.1-5.8 mm) and 0.7 mm (range, 0 – 4.1 
mm) in lateral, CC and AP direction, respectively. In lateral direction 
there was one patient and in AP direction two patients who had shifts 
larger than 2mm. In CC direction six patients had a shift below 2mm. 
One patient had a CC movement of more than 4mm in each fraction. 
There was no correlation between the differences in intrafractional 
movements of the sequential fractions. All shifts where within the 
administered margins 
Conclusions: Using Tomotherapy the median intrafractional 
movements in most patients was limited. In two cases a larger 
movement was observed. In future studies we will analyze whether 
the administered margins can be reduced in individual cases based on 
this evaluation.  
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Purpose/Objective: To develop and demonstrate the first combined 
use of MV/kV triangulation and monoscopic motion estimation in a 
clinical setting to obtain unprecedented detailed time-resolved 
measurements of internal 3D motion throughout liver SBRT treatments 
on a conventional linear accelerator. 
Materials and Methods: Ten patients with implanted gold markers 
received 11 treatment courses of three-fraction SBRT on a 
conventional linear accelerator. Two pre-treatment and one post-
treatment CBCT scans were acquired during each fraction. The CBCT 
projection images were used to estimate the internal 3D marker 
motion during CBCT acquisition with 11 Hz resolution by a monoscopic 
probability-based 2D-to-3D motion estimation method. Throughout the 
treatment delivery by 5—6 conformal (10 courses) or volumetric 
modulated arc (1 course) fields, simultaneous MV portal imaging (8 
Hz) and orthogonal kV imaging (5 Hz) were applied to determine the 
3D marker motion using either MV/kV triangulation or the monoscopic 
estimation method when marker segmentation was unachievable in 
either MV or kV images. The accuracy of the monoscopic method was 
quantified by also applying monoscopic estimation as a test for all 
treatments where MV/kV triangulation was possible. All motion is 
reported as internal motion relative to the bony anatomy.  
Results: The mean 3D RMS deviation between monoscopic estimated 
positions and triangulated positions was 0.6 mm (range, 0.3—1.4 mm), 
see Table 1, column 2. Fig.1 shows an example of observed intra-
fraction motion, relative to the mean marker position (baseline) 
during the first CBCT, for a typical treatment fraction. The mean 3D 
intra-fraction motion range during the 33 fractions was 17.6 mm 
(range, 5.6—39.5 mm). The mean 3D intra-field motion range was 11.3 
mm (2.1—35.5 mm). The mean 3D intra-fractional marker 
displacement relative to the mean position during the first CBCT was 
3.4 mm (0.7—14.5 mm). In mean, the intra-fraction 3D marker 
displacements exceeded 5.0 mm in 28.7 % of the time and in 90 % of 
the time the intra-fraction displacement was within 8.8 mm (Table 1, 
columns 3—6). The intra-fraction population systematic (SD = Σ) and 
random errors (SD = σ) were: Σ = 1.2 mm, 2.5 mm, and 1.0 mm; σ = 
1.1 mm, 3.4 mm, and 1.7 mm, in the LR, CC, and AP directions, 
respectively. The risk of large intra-fraction baseline shifts correlated 
with intra-field respiratory motion range in the CC (p = 0.040) and AP 
(p = 0.006) directions. The mean intra-fraction 3D displacement 
increased weakly as a function of elapsed intra-fraction time (2.5 mm 
after 13 min. vs. 3.7 mm after 35 min, p = 0.003). 
Conclusions: Highly detailed time-resolved internal 3D motion was 
determined throughout liver SBRT using standard imaging equipment. 
Considerable intra-fraction motion was observed. The demonstrated 
methods provide a widely available approach for motion monitoring 
that, combined with motion-adaptive treatment techniques, has the 
potential to improve the accuracy of radiotherapy for moving targets. 
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Purpose/Objective: Radiotherapy for Non-Small-Cell Lung Cancer 
(NSCLC) is limited by the risk of Radiation Induced Lung Disease 
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(RILD). RILD is typically described as consisting of an early phase of 
transient radiation pneumonitis and a late phase of persistent fibrosis. 
Previous studies have documented a local increase in radiological 
density as a function of the locally delivered dose. However, in these 
investigations only NSCLC patients receiving simple non-IMRT 
techniques were considered and little response has typically been 
observed in the low dose regions (5-10 Gy). The present study 
investigates time-dependent dose-response relationships of healthy 
lung tissue for NSCLC patients treated by IMRT. 
Materials and Methods: The study comprises 132 NSCLC patients 
treated with IMRT delivered as static field step-and-shoot or VMAT 
between October 2007 to August 2012 to a prescribed dose of 60 or 66 
Gy in 2 Gy fractions. Each patient had a series of follow-up CT scans 
which were co-registered (Elastix) to the planning CT scan using 
deformable registration. Follow-up scans were excluded from the 
study after clinical or radiological evidence of local recurrence or 
development of metastases in the thoracic region, leaving 390 
successful registrations eligible for further analysis. 3D maps of lung 
density changes were created by a voxel-by-voxel subtraction of the 
planning CT from the co-registered follow-up CT. The planned dose 
distribution was correlated to the map of density changes within the 
healthy lung tissue. The population average response was investigated 
by binning the individual dose-response curves in time intervals after 
the commencement of radiotherapy. 
Results: The figure shows the population average dose response at 
different time intervals after radiotherapy. Within the first 3 months, 
a significant increase in lung density was observed for all dose 
intervals (P<0.0001). In this time interval the density change from 
baseline increases as function of dose and reaches a plateau around 
45 Gy. At later intervals the response function changed appearance. 
The response in regions receiving 5-45 Gy decreased compared to 3 
months (P=0.014), while the plateau was replaced by a peak at high 
doses. At 6 months, regions receiving 55-60 Gy exhibited an increase 
inresponse compared to 3 months (P=0.013). After 6 months, regions 
receiving 45-60 Gy also displayed a decreased response (P=0.026). 
After 15 months the response stabilized at all dose intervals. 
Conclusions: NSCLC patients treated by modern radiotherapy 
techniques exhibit a significant increase in density of healthy lung 
tissue even at low dose levels (5-10 Gy). The transient nature of the 
response is indicative of radiation pneumonitis, while the eventual 
stabilization of the response likely is associated with fibrosis. The 
temporal evolution of the response differs in the high- and low-dose 
region. This finding suggests distinct dose-dependent time 
characteristics for the development of radiation pneumonitis and 
fibrosis. 
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Purpose/Objective: The use of parotid gland (PG) sparing intensity-
modulated radiotherapy (IMRT) significantly reduces high grade 
xerostomia. Water alone is a poor oral mucosal lubricant; the 
inorganic and organic salivary components are suggested to increase 
moisture retention on the mucosa. PG saliva comprises ~70% and 30% 
of stimulated and unstimulated saliva volume respectively. Despite 
the use of PG sparing IMRT, rates of high grade xerostomia are ~35% at 
1 year. Data on saliva composition analysis post radiotherapy (RT) is 
limited pre-IMRT due to poor residual salivary flow. We present an 
analysis of PG saliva flow rate and composition for patients treated 
with IMRT within four trials at The RMH. 
Materials and Methods: Samples were collected in the PARSPORT trial 
(CRUK/003/005) and 3 single institution, phase 2 studies (Midline (CCR 
2588), Dose Escalation (CCR1978) and Nasopharynx (CCR 2608)). 
Stimulated and unstimulated PG salivas were collected from right and 
left glands using Lashley cups (2% citric acid). Collect was at baseline 
(BL), 3, 6, 12 and 24 months(m) post-IMRT. Samples were suitable for 
analysis if a pre-IMRT and chemotherapy (BL) and ≥1 subsequent 
sample, of adequate volume (>150µl) were collected. Salivas were 
analysed for protein and ionic components using ELISA (IgA, B2M and 
lactoferrin), BCA assay (total protein) and ICP-mass spectrometry 
(Ca2+, Na+). Flow rates were determined gravitometrically (1g=1ml). 
Samples were statistically analysed for early (3-6m post-IMRT) and 
late (12-24m post-IMRT) changes using wilcoxon signed rank or paired 
t-tests and reported as % change from BL. 
Results: Twenty-one patients provided 120 samples for analysis. 
Seventeen patients were male, mean patient age was 58.4 yr and 14 
received chemotherapy. Mean PG RT dose was 27.8Gy. Sequential 
results (table 1) showed significant changes in several parameters a 
persistent (early and late) increase in lactoferrin. An early increase in 
B2M and Na+ concentration and an early decrease in PG saliva flow 
rate. Both resolved to normal after 12m. Stimulated calcium 
concentration (Ca2+) was persistently decreased by ~20%. All other 
parameters were not significantly altered. 
 
 
% of BL (100%), Median 
(IQR) 
Unstimulated PG Saliva 
(*=p<0.05) 
% of BL (100%), Median 
(IQR) 
Stimulated PG saliva 
(*=p<0.05) 
Parameter 3-6m (n=24) 
12-24m 
(n=12) 
3-6m 
(n=17) 
12-24m 
(n=12 
Total Protein 
Concentration n.s. n.s. n.s. n.s.  
Total Protein 
Secretion Rate 
38.0%* 
(10.7-
101.0) 
n.s. n.s. n.s.  
PG Saliva Flow 
Rate 
39.3%* 
(25.0-
120.8) 
n.s. 45.1%* (21.0-99.2) n.s.  
IgA 
Concentration n.s. n.s. n.s. n.s.  
B2M 
Concentration 
130.4%* 
(77.6-
200.9) 
n.s. 
125.2%* 
(98.4-
224.3) 
n.s. 
LF Concentration 
289.5%* 
(119.7-
626.7) 
386.9%* 
(574.4-
641.6) 
279.1%* 
(165.6-
583.5) 
225.5%* 
(89.4-
317.6) 
Ca2+ 
Concentration n.s. n.s. 
77.7%* 
(63.9-
83.7) 
80.5%* 
(73.1-
107.2) 
Na+ 
Concentration n.s. n.s. 
126.2%* 
(114.3-
345.2) 
n.s. 
 
Conclusions: An elevated Na+ concentration suggests transient ductal 
dysfunction. Salivary flow rates returned to baseline after 12 months 
indicating good functional recovery post IMRT. Persistently reduced 
Ca2+ concentration may affect mucin-mucin interactions and mucin 
retention with water on the buccal mucosa. This may also have a 
negative impact on long-term dental remineralisation. 
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Purpose/Objective: Since December 2011, we planned adjuvant 
radiotherapy for breast cancer with fixed angle Intensity Modulated 
Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy 
